This article was originally published in The Gray Sheet
Executive SummaryThird-quarter substance abuse test sales were up 31% to approximately $3.6 mil. compared with the year-ago period, the firm reports. During a Nov. 9 earnings call, CEO Douglas Michels cited three cases in which results from OraSure's Intercept oral fluid drug test were accepted as evidence by a court. "The legal defensibility of our test is very important to our customers, and these cases represent yet additional confirmation of the reliability and accuracy" of the oral fluid test, Michels explained...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.